Alnylam charts ambitious five-year plan as sales of key drug miss expectations Company’s sales top $3B, but quarterly results show challenge of delivering on high targets +++

https://www.statnews.com/2026/01/11/alnylam-five-year-plan-amvuttra-investors-jpm-2026/ By Matthew HerperJan. 11, 2026 Senior Writer, Medicine, Editorial Director of Events FDA puts off Stoke’s request for faster filing of severe epilepsy drug Agency asks for more information on Dravet syndrome treatment https://www.statnews.com/2026/01/11/stoke-therapeutics-fda-expedited-submission-severe-epilepsy-zorevunersen-dravet/ By Adam FeuersteinJan. 11, 2026 Senior Writer, Biotech How AI is supercharging antibiotic discovery https://www.statnews.com/sponsor/2026/01/12/how-ai-is-supercharging-antibiotic-discovery/